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Arachidonic acid and its metabolites play important roles in
renal tubular function. This overview will review general char-
acteristics of arachidonic acid metabolism, focus on the char-
acterization and regulation of renal acyihydrolases that gener-
ate arachidonic acid from phospholipids, examine what is
known about the production of arachidonic acid metabolites
along the nephron, and explore what the potential roles of these
metabolites are in physiological and pathophysiological states.
Due to space limitations it is not possible to review this
extensive topic including the glomerulus as well as the rest of
the nephron, renal interstitium, and vasculature. Since this
monograph is focused upon the tubulointerstitium, we will not
discuss the various aspects of arachidonic acid metabolism in
the glomerulus but only refer to glomerular cells when a
mechanism pertinent to the tubulointerstitium is best illustrated
by work done on a glomerular cell.
Overview of arachidonic acid metabolism
Arachidonic acid, which is taken into the body in the diet or
can be synthesized from the essential dietary fatty acid, linoleic
acid (18:2w6), is in large part esterified to the sn-2 position of
phospholipids. The release of free arachidonic acid is believed
to be the rate-limiting step in eicosanoid synthesis [1]. Release
of arachidonic acid can occur as a consequence of a number of
different mechanisms (Fig. 1) including: 1) a direct action of
phospholipase A2 on a phospholipid to produce free arachidonic
acid and lysophospholipid; 2) the sequential action of phospho-
lipase C, resulting in the formation of diacylglycerol, followed
by the release of free fatty acid by diacyiglycerol lipase; 3) the
sequential action of phospholipase C, diacylglycerol kinase and
phosphatidic acid specific phospholipase A2; and 4) the sequen-
tial action of phospholipase D [2] followed by phosphatidic
acid-specific phospholipase A2. In addition triglycerides can
serve as a source of arachidonic acid via the action of triglyc-
eride lipase. This latter mechanism may be of particular impor-
tance in the inner medullary interstitial cells which have large
lipid droplets, the content of which decreases with physiologi-
cal states associated with enhanced renal prostaglandin produc-
tion [3, 41. In most systems phospholipase A2 is believed to be
the primary effector enzyme for arachidonic acid release [1].
The lipid origin of arachidonic acid varies depending upon the
cell type and the agonist used to stimulate release. The levels of
free arachidonic acid are influenced, not only by these release
mechanisms, but also by very efficient reacylation processes.
There are three possible pathways for further metabolism of
arachidonic acid. Prostaglandin endoperoxide (PGH2) synthase
can transform arachidonic acid into prostaglandins. There are
two parts to this enzymatic activity residing in a single protein
[5]. PGH2 synthase has a cyclooxygenase component which
catalyzes the insertion of two molecules of oxygen into arachi-
donic acid to form PGG2. The second enzymatic activity is a
hydroperoxidase-induced two-electron reduction of the 15-
hydroperoxy group of PGG2 to yield PGH2. Nonsteroidal
antiinflammatory agents inhibit the cyclooxygenase component
of PGH2 synthase. This is an 02 consuming process and results
in the generation of reactive oxygen species which may, under
certain circumstances, be toxic to the cell. PGH2 is then
converted to the biologically active prostaglandins—PGE2,
PGD2, PGF2, PGI2 (prostacyclin) and thromboxane A2 (TxA2).
An alternative pathway for arachidonic acid metabolism is
the lipoxygenase pathway. This enzyme catalyzes a dioxygen-
ase reduction resulting in the formation of 5,8,12 or 15-
HPETE' s (hydroperoxyeicosatetraenoic acids). The leukot-
rienes are products of further metabolism of 5-HPETE and the
HETE's (hydroxyeicosatetraenoic acids) are products of 8,12,
or 15-HPETE.
A third pathway for arachidonic acid metabolism is the
cytochrome P450 monooxygenase. This system results in the
oxidative transformation of a number of endogenous and exog-
enous substrates including saturated fatty acids, leukotrienes,
prostaglandins, steroids, and hydrocarbons [61. Attesting to the
relevance of this system to renal function is the recent obser-
vation that epoxyeicosatrienoic acids have been isolated from
human urine [71.
It is likely that cellular pools of free arachidonic acid are not
homogeneous. Peptide hormones, for example, may result in
release of arachidonic acid into pools with ready access to
enzymes that will metabolize the arachidonic acid into specific
prostaglandins, lipoxygenase products, or other metabolites [8].
The first step in the generation of prostaglandins, lipoxygen-
ase, or P450 products is the generation of arachidonic acid by
the action of acyihydrolases on lipids, primarily phospholipids.
We will summarize what is known about renal acyihydrolases.
Acylhydrolases
Phospholipase A2
© 1991 by the International Society of Nephrology
Phospholipase A2 (PLA2) is a ubiquitous enzyme, which
exists in both secretory and intracellular forms. The secretory
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Fig. 1. Pathways for generation of free
arachidonic acid (AA) and the subsequent
metabolism of arachidonic acid. Arachidonic
acid can be cleaved from the sn-2 position of
phospholipids such as phosphatidyicholine
and phosphatidylinositol by the action of
phospholipase A2 (PLA2) leaving
lysophosphatidylcholine (Lyso-PC) or
lysophosphatidylinositol (Lyso-PI).
Alternatively free arachidonic acid can be
generated by the sequential activity of
phospholipase C (PLC), producing
diacyiglycerol (DAG), which is then
metabolized by DAG-lipase, thus generating
free arachidonic acid and monoacylglycerol
(MAG). Phosphatidic acid (PA), which can be
produced directly from phospholipids by the
action of phospholipase D (PLD), or indirectly
due to the phosphorylation of diacylglycerol
by DAG-kinase can serve as a substrate for
phosphatidic acid-specific-phospholipase A2(PA-PLA2), generating free arachidonic acid
and lysophosphatidic acid (lyso-PA). Once
free arachidonic acid is liberated it can be
metabolized via the cyclooxygenase,
lipoxygenase, or cytochrome P450 mixed-
function oxidase systems, as described in the
text. Abbreviation FA is fatty acid.
forms of the enzyme are prominent components of snake and
insect venoms, as well as pancreatic extracts. These enzymes
are generally small proteins (molecular wt -l2,000 to 18,000
daltons), which depend upon calcium for activity and have very
high specific activities (>100 tmol/min/mg) [9]. Many of these
enzymes have been purified and their amino acid sequences
determined [10]. In general, much less is known about intra-
cellular forms of PLA2, which are involved in the hormonal
regulation of arachidonic acid release. It was generally believed
that intracellular forms of the enzyme were also Ca2 requiring
enzymes. More recently, both Ca2 dependent and indepen-
dent forms of the enzyme have been identified, and some
intracellular forms have specific activities approaching those of
the secretory forms of PLA2 [11]. It is also apparent that these
intracellular enzymes represent distinct proteins. Antibodies
raised against intracellular mitochondrial PLA2, for example,
fail to cross react with a variety of secretory forms of PLA2
[121, and even fail to recognize other intracellular forms of the
enzyme. As has become clear in the study of other phospholi-
pases such as inositol-specific phospholipase C [13], PLA2
constitutes a family of proteins.
The regulation of PLA2 is multifaceted (Fig. 2). Inner med-
ullary slices labelled with '4C-arachidonic acid release 14C-
arachidonic acid in response to increased levels of Ca2 and
A23 187 in the buffer [141. This is associated with corresponding
reductions in amount of '4C-arachidonic acid in phosphatidyl-
choline, phosphatidylethanolamine, and phosphatidylinositol.
W-7, a calmodulin inhibitor, inhibited the arachidonic acid
release. When the 100,000 xg particulate fraction was incu-
bated with exogenous 14C-arachidonic acid-phosphatidyicho-
line there was a Ca2 dependent release of '4C-arachidonic acid
from the phospholipid. PLA2 activity was observed at 100 IIM
calculated free Ca2 concentration, and was increased five- to
ninefold over Ca2-free conditions when the buffer Ca2 con-
centration was 5 msi. W-7 inhibited this activity [141. The pH
optimum was 9.0 when pH was tested over a range of 5 to 9.
Urea, at 800 mOsm, suppressed PLA2 activity while NaCI, at
equivalent osmolarity, had no effect.
When mesangial cells were rendered permeable with digito-
nm and exposed to levels of free calcium concentration mea-
sured in the intact cells stimulated with vasopressin, there was
enhanced arachidonic acid release and PGE2 synthesis when
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Fig. 2. Schematic representation of various forms of regulation of
phospholipase A2 as derived from experiments in our laboratories on
the renal mesangial cell. The dotted lines represent pathways which are
less well understood. Agonists such as vasopressin (AVP), which
activate phospholipase C (PLC), likely via a G protein (Go), increase
cytosolic free calcium concentration (Ca2) due to inositol trisphos-
phate (1P3)-induced release of calcium from intracellular stores. Cal-
cium activates phospholipase A2 (PLA2) directly and also mediates the
translocation of the enzyme to the cell membrane. The diacylglycerol
formed as a result of PLC activation will activate protein kinase C
(PKC) which enhances the calcium dependent activation of PLA2. This
potentiation of PLA2 activity by protein kinase C could occur either by
direct phosphorylation of the enzyme or indirectly by phosphorylation
of a PLA2 modulatory protein. Epidermal growth factor (EGF), by
contrast, activates PLA2 by a mechanism that does not require an
activation of PLC or associated activation of protein kinase C or
increases in cytosolic free calcium concentration. This activation is not
well understood. It may involve G proteins (Go') but, if so, not a
pertussis toxin-inhibitable G protein. Since EGF activation is known to
be associated with tyrosine kinase activation, tyrosine kinase substrates
may be involved.
compared with permeabilized cells exposed to calcium concen-
tration ([Ca2]) measured in resting cells (<100 nM) [15]. Thus
the intracellular PLA2 is Ca2-dependent over the "physiolog-
ical range" of [Ca2i variation. In addition, distinct isoforms of
PLA2 appear to be regulated by guanine nucleotide binding
proteins (G-proteins) [16, 171, activation of protein kinase C
[15], Na/H exchange activity [18], membrane potential [19],
and perhaps specific PLA2 regulatory proteins [20, 211.
In renal cells activation of protein kinase C may play an
important role in the regulation of PLA2 activity. In glomerular
mesangial cells we demonstrated that when PMA (phorbol
myristate acetate) was added to intact cells along with the Ca2
ionophore, A23 187, there was a marked potentiation of the
effect of A23187 on arachidonic acid release. Likewise, when
PMA was added to permeabilized cells clamped at 500 to 2200
nM [Ca2 ], there was a marked increase in PGE2 production.
PMA alone had no effect upon PGE2 production after 10
minutes of stimulation of intact cells or in cells permeabilized
under conditions where [Ca2] was clamped at levels less than
200 flM [153. Thus we concluded that protein kinase C modu-
lates the Ca2 dependent activation of PLA2 and suggested that
this effect may be mediated by phosphorylation of PLA2 itself
or PLA2 modulatory proteins. In Madin Darby canine kidney
(MDCK) cells PMA alone has been reported to increase ara-
chidonic acid release, but this requires longer periods of expo-
sure to the phorbol ester [22].
Increased arachidonic acid release is also seen following
stimulation of mesangial cells with epidermal growth factor
(EGF) which does not in itself cause an activation of phospho-
lipase C or rise in intracellular free Ca2 levels [23, 24]. When
mesangial cells were stimulated with platelet derived growth
factor (PDGF), increases in arachidonic acid release were
observed prior to detectable increase in cytosolic [Ca211 and
inositol trisphosphate levels, suggesting that PLA2 activity was
increased prior to a significant increase in phospholipase C
activity [25]. Interleukin I enhances arachidonic acid release
from papillary collecting duct cells in culture [26]. Since recom-
binant IL-i does not increase phosphatidylinositol-specific
phospholipase C activity in cells where this has been examined
[27], it is probable that this activation of arachidonic acid
release is also [Ca2] independent.
In many studies changes in PLA2 activity have been inferred
from observed changes in arachidonic acid release [28—30]. To
directly examine PLA2 enzymatic activity we have recently
developed a cell-free assay to measure PLA2 activity with
exogenous phospholipid substrate. Employing this assay, a
hormonally regulated form of PLA2 has been identified [31, 32,
Note added in proof A]. Treatment of mesangial cells with
PMA, AVP or EGF results in a stable modification of enzymatic
activity, which is detected at saturating Ca2 concentrations,
and survives fractionation of the enzyme on several columns
[23, 311. Pretreatment of mesangial cells with a high concentra-
tion of PMA, which results in down-regulation of protein kinase
C, abolishes the AVP stimulation, suggesting that it is mediated
through activation of protein kinase C. EGF stimulation, on the
other hand, remains unaffected, arguing for a protein kinase C
independent mechanism of regulation. This enzyme is distinct
from many of the previously characterized forms of PLA2. It is
a large soluble protein which appears to associate with mem-
brane fractions in a Ca2 dependent manner [31, 33]. Hormone-
induced increases in intracellular Ca2 will presumably cause
the enzyme to translocate to the membrane. This may represent
an additional form of regulation.
This enzyme is the major soluble form of PLA2 in extracts
from whole kidney. Purification of the enzyme from kidney
has shown it to be a 110 kDa protein (Note added in proof A).
The enzyme has a requirement for Ca2, and is activated at
physiologic concentrations of Ca2t It has a specificity for
unsaturated fatty acid side chains of phosphatidyicholine and
phosphatidylethanolamine, with low activity towards phospha-
tidylinositol. A similar enzyme has been partially characterized
in a macrophage cell line RAW 264.7 [34] and peritoneal
macrophages [35]. To determine the specific role this enzyme
plays in arachidonic acid metabolism, it will be necessary to
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develop specific antibodies and clone the gene encoding for this
protein in order to examine its regulation.
Kidney extracts also contain a smaller molecular weight form
of PLA2. A small (Mr 14 kDa) form is enriched in mitochon-
drial fractions, and is only activated at micromolar levels of
Ca2. Both the cytosolic large form and mitochondrial smaller
form are increased in activity with ischemia and reperfusion in
the rat kidney (unpublished observations). Mitochondrial PLA2
activity is also enhanced in vitro by exposure of isolated renal
mitochondria to Ca2 and reactive oxygen species using a
model we have developed to stimulate ischemia and reperfusion
in vivo [36, 37].
In non-renal tissues other intracellular forms of PLA2 have
been purified. Sheep platelets contain a soluble PLA2 which is
activated at physiologic Ca2 (<1 LM) [38]. Spleen contains
both membrane associated and soluble forms of the enzyme,
both of which are small molecular weight forms requiring high
Ca2* concentrations for maximal activity [39, 40]. The soluble
form appears to be identical to pancreatic secretory PLA2.
Another membrane associated form of the enzyme has been
isolated from P388D1 macrophages [41]. This is also a low
molecular weight form. Finally Ca2 independent forms of
PLA2 have been partially purified from cytosolic fractions [11].
PLA2 modulatory proteins
Much attention has recently been focused on a family of
Ca2-phospholipid binding proteins called "lipocortins", "lipo-
modulins", or "renocortins" [42—44]. These proteins were
shown to be PLA2 inhibitors in vitro. Data that these proteins
were secreted in response to glucocorticoids, provided an
attractive mechanism for PLA2 regulation. Rat renomedullary
interstitial cells in culture produce two proteins in response to
dexamethasone which have PLA2-inhibitory action in an assay
in vitro, where substrate was limiting, and reduce PGE2 pro-
duction in intact control cells [42]. Lipocortin land II have been
purified and cloned [45], and we have found these proteins, as
well as the mRNA's encoding for them, to be present in large
amounts in mesangial cells [46]. More recently it has been
shown that lipocortin inhibition of PLA2 occurs by sequestra-
tion of phospholipid substrate, and not a direct interaction with
the enzyme [47]. Nevertheless, a role for PLA2 modulatory
proteins in cellular PLA2 regulation remains a distinct possibil-
ity [48]. In fact, a modulatory protein which activates PLA2 has
been characterized and purified [49]. This protein appears to be
immunologically related to mellitin, a substance with known
PLA2 stimulatory characteristics. Identification of isoforms of
PLA2 involved in arachidonic acid metabolism will facilitate the
search for PLA2 modulatory proteins.
Diacyiglycerol lipase
Craven and DeRubertis [14] measured diacyiglycerol lipase
activity in the 100,000 xg particulate fraction from the renal
medulla. They found that ['4C]-arachidonic acid release from
['4C]-arachidonic acid-diglyceride in the presence of the partic-
ulate fraction was enhanced by Ca2 with the optimal Ca2
concentration being approximately 100 /LM. The pH optimum of
the enzyme was 7.0 to 7.5. Eighty-five to 95% of the homoge-
nate diacylglycerol lipase activity was found in the particulate
fraction. The activity was not inhibited by W-7, but was
inhibited by 800 mOsm urea.
Phosphatidic acid specific phospholipase A2
Craven and De Rubertis [14] found that phosphatidic acid
specific PLA2 activity in the renal medulla was also Ca2
dependent with optimal stimulation occurring at 25 M Ca2
concentration. Eighty-nine to 96% of total homogenate activity
was in the particulate fraction. The pH optimum was in the
range of 7 to 7.5. Activity was measured against phosphatidic
acid under pH and Ca2 conditions where there was no
acyihydrolase activity against phosphatidyleholine or phospha-
tidylethanolamine suggesting specificity of the enzymatic activ-
ity, although not precluding the possibility that the greater
solubility of phosphatidic acid might enhance substrate avail-
ability to the enzymatic activity. W-7 had no effect on this
activity. Urea (800 mOsm) inhibited the activity. In contrast to
other acylhydrolases 400 or 800 mOsm NaC1 markedly inhibited
the activity of the phosphatidic acid specific PLA2.
Kidney acyihydrolases and hypertension
Dunn [50] and Limas and Limas [51, 52] found that prosta-
glandin synthetase activity was greater in adult spontaneously
hypertensive rats (SHR) than in the WKY control rats. Limas
and Limas also found that enhanced PGE2 synthesis by SHR
kidney renomedullary microsomes and tissue slices could be
found when 2-[ 1- '4C1 arachidonyl phosphatidylcholine was
used as substrate and suggested that there was enhanced
microsomal phospholipase activity in SHR animals. Further
evidence that this activity represented PLA2 was provided by
data indicating that '4C-arachidonic acid incorporated primarily
into phosphatidyicholine was released after exogenous PLA2
addition or exposure to bradykinin or angiotensin II. Mepa-
crine, a PLA2 inhibitor, decreased the release of arachidonic
acid. Kawaguchi and Yasuda found that enhanced PLA2 activ-
ity was found in cortical and medullary microsomes from stroke
prone SHR rats when compared with WKY controls [53]. This
activity increased with age (and blood pressure) in the SHR
animals but not in controls. Phosphatidylethanolamine was the
preferred substrate and maximal activity was achieved at a
Ca2 concentration of 5 mri. The authors suggested that the
enhanced PLA2 activity in the SHR animals was related to
increases in intramicrosomal Ca2 in these animals. In a
subsequent study this group found that enhanced phospholipase
C activity was found in the cortical and medullary cytosolic
fractions from the stroke-prone SHR animals. Furthermore,
they found enhanced diglyceride lipase activity in the microso-
mal fractions from the SHR animals [54].
Cyclooxygenase products
While it is generally believed that the levels of free arachi-
donic acid are rate limiting for prostaglandin synthesis it has
been demonstrated that PGH2 synthase, as well as some of the
enzymes which convert PGH2 to various prostaglandins and
thromboxanes, may also be regulated. PGH2 synthase has been
cloned from sheep vesicular gland (Note added in proof B). The
molecular weight of the unglycosylated enzyme, lacking the 24
amino acid signal sequence, is 65,621. The enzyme is a glyco-
protein. A serine, that is acetylated by aspirin, is at position
530, close to the carboxyl terminus. Most prostaglandin syn-
thase activity in the kidney is found in the papilla with decreas-
442 Bonventre and Nemenoff. Arachidonic acid metabolism
ing amounts proceeding through medulla and cortex [50, 55].
This activity is found primarily in the microsomal fraction [51].
Ureteral and venous obstruction have been reported to
enhance cyclooxygenase activity and ureteral obstruction in-
creases thromboxane synthase activity [56—58]. In human kid-
neys immunohistochemical staining with antiserum to PGH2
synthase is localized to collecting duct, thin ascending limb
epithelial cells, and possibly mesangial cells [59]. Staining with
antiserum to prostacyclin synthase is localized to the peritubu-
lar capillaries, renal interstitial cells and glomerular mesangial
cells. While PGH2 synthase staining is comparable to normal
kidneys in renal tissue from patients with acute tubular necro-
sis, tubulointerstitial nephritis, or liver disease without the
hepatorenal syndrome, staining is markedly suppressed in
kidneys from patients with hepatorenal syndrome [59]. The
investigators who reported these findings suggested that the
reduced medullary PGH2 synthase activity may explain the
reduced prostaglandin E2 excretion observed with the hepato-
renal syndrome and may relate in an important way to the
pathophysiology of the syndrome.
With the exception of PGI2 [60], prostaglandin synthesis is
greater in the renal medulla than it is in the cortex. Cortical
tubule production of prostaglandins is very low [61—63]. By
contrast there is significant production in the glomerulus, outer
medulla and inner medulla [61—65]. Kirschenbaum et al [611
found that isolated rabbit cortical collecting tubules produce
prostaglandins. Schlondorff, Satriano and Schwartz [631 re-
ported that PGE2 synthesis increases when moving from the
branched connecting tubule to the cortical and medullary
collecting tubules. A23 187 induced enhanced synthesis in each
segment to an extent predicted by the basal levels of PGE2
synthesis.
Farman, Pradelles and Bonvalet [64] examined the profile of
PGE2 and PGF2 synthesis along the nephron of the rabbit by
preparing isolated nephron segments and incubating them with
arachidonic acid. PGE2 was the primary prostaglandin pro-
duced in every tubular segment. A progressive increase in
prostaglandin synthesis occurred along the distal nephron. The
major site of PGE2 and PGF2 synthesis was the collecting
tubule, especially the medullary collecting tubule. Of the more
proximal nephron segments the thin descending limb was the
only segment with significant prostaglandin production. PGF2
synthesis was 50 to 100 times lower than that of PGE2 in each
segment except for the glomerulus where they were approxi-
mately equivalent. Synthesis of 6-keto-PGF1 was extensive in
the medullary collecting duct but even greater in the glomeru-
lus. The rate of thromboxane B2 synthesis was also greatest in
the glomerulus with the cortical and medullary collecting duct
also active producers of TxB2. Medullary interstitial cells
produce PGE2 and PGF2 in vitro [28, 651, and likely contribute
in an important way to the papillary prostaglandin production.
Modulation of prostaglandin production. Yasopressin in-
creases cortical collecting duct prostaglandin production [61,
631 and the prostaglandins inhibit the antidiuretic action of
vasopressin [61]. Schlondorff et al [63] found that bradykinin
enhanced PGE2 synthesis in cortical and medullary collecting
tubules from adult rabbits. Schuster, Kokko and Jacobson [66]
showed that bradykinin inhibited the hydroosmotic effect of
vasopressin via a prostaglandin-dependent mechanism.
Jaisser et al [67] have reported that, whereas AVP increases
POE2 synthesis in cortical collecting ducts, the V2 agonist,
dDAVP, exerted a very weak response. This weak response to
dDAVP is contrary to the results of Kirschenbaum et al [61] and
has been taken as evidence that the AVP-induced PGE2 re-
sponse is mediated by a V1 vasopressin receptor.
A number of investigators have examined the control of
prostaglandin synthesis in collecting duct cells in culture. Using
this preparation the following agonists and manipulations have
been found to enhance prostaglandin production: AVP [68, 69],
bradykinin [68], angiotensin II [68], and hypertonicity [68, 69].
Teitelbaum, Mansour and Berl have reported that cAMP inhib-
its PGE2 production, possibly by an effect on phospholipase A2
[70]. Medullary interstitial cells in culture produce prostaglan-
dins in response to AVP, angiotensin II and bradykinin [65].
Actions of cyclooxygenase products in the kidney
Cyclooxygenase products have many actions on the renal
tubular cell directly and on the renal vasculature supplying the
tubular cells [71]. In this review it is not possible to give an
adequate overview of these multiple effects which are the topics
of many recent reviews [72]. We will, however briefly summa-
rize primary actions of these eicosanoids that may be relevant
to tubulointerstitial physiology and pathophysiology.
Renal blood flow. In general PGI2, PGF2, and PGA2 are
vasodilators and TxA2 a vasoconstrictor in the kidney [71—73].
Under normal conditions prostaglandins likely play a minimal
role in blood flow regulation, as reflected by the fact that
systemic treatment with nonsteroidal antiinflammatory agents
has little effect on renal blood flow or GFR. By contrast, with a
compromised circulation, as occurs with hemorrhage, conges-
tive heart failure, or cirrhosis, inhibition of cylooxygenase
causes marked decreases in renal blood flow and GFR [74, 75].
This is presumed to be due to the inhibition of the production of
vasodilatory prostaglandins. Prostaglandins act to counteract
the vasoconstrictive tendencies of angiotensin II and vasopres-
sin which are present in large amounts in these pathophysiolog-
ical states. The effects of prostaglandins on renal blood flow
counterbalance vasoconstrictive influences, such as the stimu-
lated sympathetic nervous system, even when the renin-angio-
tensin system has been suppressed [76]. Prostaglandins may
also affect GFR via their action on the mesangial cell. Agents
such as AVP and angiotensin II increase cytosolic [Ca2] in
mesangial cells [77] and cause mesangial cell contraction which
may result in a reduction in Kf. This effect is counteracted by
vasodilatory prostaglandins which are produced by the mesan-
gial cells [15] in response to these agonists and which cause
relaxation of the mesangial cells [78].
Renin secretion. Prostaglandins are potent stimuli of renal
renin release. Arachidonic acid infusion into the kidney results
in enhanced renin production that is inhibited by indomethacin.
Renin production from both filtering and nonfiltering kidneys is
also enhanced by prostaglandin infusion in vivo [79]. Whorton
et al. found that P012, PGE2, PGF2, and PGE1 released renin
from rabbit cortical slices with PGE2 and POE1 being the most
effective agents [801. Beierwaltes et al found PGI2 to be most
effective in stimulating renin release from isolated glomeruli
[81]. j3-adrenergic stimulation of renin release occurs, in large
part, by a prostaglandin-independent mechanism [79, 82, 83]
although there is some evidence to suggest involvement of the
pro staglandin system in this process [84]. Prostaglandins also
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appear to be important for the renin release which occurs
secondary to changes in macula densa NaC1 delivery 185].
Sodium excretion. When PGE2 is infused intravenously or
directly into the renal artery of animals that are salt replete
there is a marked natriuresis [861. This natriuresis is likely due
in part to the above described effects on renal blood flow but
part of the natriuresis is likely also related to direct effects on
tubular sodium transport. Furthermore, cyclooxygenase inhib-
itors markedly reduce the natriuresis associated with volume
expansion [87].
PGE2, the predominant prostaglandin formed in the kidney,
alters transport characteristics in the thick ascending limb and
collecting duct and possibly in the proximal tubule. Kinoshita,
Romero and Knox [88] have recently shown that interstitial
infusion of PGE2 increases, whereas PG!2 decreases, proximal
tubule sodium reabsorption in rats. PGE2 inhibits NaCI reab-
sorption from the ADH- or DOCA-stimulated ascending limb
[89—911. Another group [92], however, was unable to find an
inhibitory effect of PGE2. Miyanoshita, Terada and Endou [931
have reported that furosemide, ethacrynic acid and bumetanide
significantly increase PGE2 production in the thick ascending
limb and the effects of PGE2 on this nephron segment may
facilitate the diuretic action of these diuretics.
In the collecting duct PGE2 inhibits sodium reabsorption
[94—96]. Stokes [97] has argued that PGE2 acts to inhibit apical
Na entry into the cells of the isolated collecting duct since it
indirectly increases lumen-to-bath K movement in a manner
similar to amiloride, rather than decreases K permeation as
seen with ouabain. Jabs, Zeidel and Silva [98], however, found
that PGE2 inhibited ouabain-sensitive oxygen consumption and
86Rb uptake in freshly isolated inner medullary collecting duct
cells, and NaKATPase activity in inner medullary mem-
branes.
Water excretion. Prostaglandins alter the concentrating abil-
ity of the kidney in a number of ways. Since prostaglandins alter
thick ascending limb Na reabsorption, they would be expected
to alter the medullary concentration gradient and hence free
water reabsorption. Enhanced medullary blood flow mediated
by local prostaglandin synthesis results in partial wash-out of
the medullary solute gradient [99]. Agents which inhibit pros-
taglandin synthesis decrease vasa recta blood flow [99]. It has
been known for some time that prostaglandins of the E class
inhibit AVP-induced water flux across the toad bladder [1001
and isolated collecting tubule [101]. This inhibition occurs, at
least in part, because of inhibition of the generation of cAMP by
AVP [102]. Thus, AVP, by promoting the formation of pros-
taglandins, inhibits its own action on water permeability. Pros-
taglandins also reduce urea reabsorption from the collecting
duct [103] and this effect may interfere with "urea recycling,"
which is important for maintenance of medullary solute con-
centrations. Nonsteroidal antiinflammatory agents, which in-
hibit prostaglandin production, increase concentrating ability
[104]. In addition to these effects of prostaglandins on free
water reabsorption these agents would be expected to inhibit
free water excretion also due to their inhibition of thick ascend-
ing limb Na reabsorption.
Lipooxygenase products
Little is known about the generation of non-cyclooxygenase
products of arachidonic acid in the kidney. Most information
about the lipoxygenase enzymes comes from other tissues. The
human leukocyte 15-lipoxygenase has been purified to homo-
geneity [105]. Based on partial N-terminus protein sequence
data there was 71% homology with rabbit reticulocyte 15-
lipoxygenase and 36% homology with rat basophilic leukemia
5-lipoxygenase [106]. The l5-lipoxygenase is activated by cal-
cium in crude homogenates but the purified enzyme is indepen-
dent of calcium, suggesting the possible presence of a calcium-
dependent activator. Recently a membrane protein which is
necessary for leukotriene synthesis in intact cells has been
isolated and cloned [106—108]. This protein has been named
five-lipoxygenase activating protein (FLAP) and its presence
indicates that the regulation of the various lipoxygenases will
likely be as diverse as the above described regulation of the
acylhydrolases.
To date there is no evidence for 5-lipoxygenase activity and
subsequent leukotriene production by renal tissue. Hamberg
found that 12-HETE (12-hydroxyeicosatetraenoic acid) was
generated by guinea pig kidney homogenates. Winokur and
Morrison [109] reported the production of 12- and 15-HETE by
soluble fractions of rabbit medullary homogenates. Jim et al
[110] found lipoxygenase activity in the cortex of rat kidney.
l2-HETE was produced by homogenized glomeruli, glomerular
epithelial cells in culture and cortical tubules, although it was
not clear whether this cortical tubule activity was due to
cortical epithelial cells, glomeruli or vascular structures which
contaminated the tubule preparation. 12- and l5-HETE have
been reported to be produced by mesangial cells in culture
[111]. In a recent study Gordon, Figard and Spector [112]
showed that MDCK cells could convert 12-HETE to a more
polar metabolite: 8- hydroxyhexadecatrienoic acid by a process
that does not involve the lipoxygenase, cytochrome P450 or
mitochondrial /3-oxidation pathways.
Lipoxygenase products may affect transmembrane transport
by effects on channels. The /3y-subunits of G-proteins have
been reported to activate potassium channels in atrial cells by
stimulating production of lipoxygenase intermediates [113]. A
similar phenomena has been described in epithelial cells with
lipoxygenase intermediates involved in Na channel regulation
[114]. Lipoxygenase products may affect other components of
arachidonate metabolism. In the platelet and neutrophil the
monoHETEs inhibit PLA2 activity [115]. In MDCK cells 12-
HETE inhibits the formation of PGE2, the primary prostaglan-
din product of these cells [116].
While PGE2 and prostacyclin enhance renin secretion from
juxtaglomerular cells [100], 12-HETE and 15-HETE and their
precursors 12- and 15-HPETE (12 and l5-hydroperoxyeico-
satetraenoic acids) inhibit renin secretion from rat cortical
slices [117]. By contrast, 5-HPETE and leukotrienes had no
effect upon renin secretion.
Cytochrome P450 monooxygenase products
Cytochrome P450 monooxygenases represent a family of
enzymes [118]. Mixed function oxidase activity involves the
hemoprotein, cytochrome P450, together with a flavoprotein
reductase (NADPH cytochrome P450 reductase) and phos-
phatidylcholine [118]. This enzyme system results in the gener-
ation of a number of different epoxyeicosatrienoic acids
(EET's) which can then be rapidly converted to dihydroxyeico-
satrienoic acids (DHET's).
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Oliw et al [1191 in 1981, incubated arachidonic acid with
rabbit renal cortical supernatants and microsomes and reported
the formation of 11, 12-dihydroxy-5,8, 14-eicosatrienoic acid and
14,15-dihydroxy-5,8,ll-eicosatrienoic acid, as well as 19- and
20-hydroxyeicosatrienoic acid, 1 9-oxoeicosatetraenoic acid and
eicosatetraen- 1 ,20-dioic acid.
At the same time, Winokur and Morrison [109] and Morrison
and Pascoe [120] reported that the renal cortex contained an
active NADPH-dependent monooxygenase that converted ara-
chidonic acid into I 9-hydroxy- and 20-hydroxy arachidonic acid
as well as 19-ketoarachidonate and dicarboxylic acid. Both
groups of investigators proposed that the enzymatic conver-
sions of arachidonic acid were due to the presence of a
cytochrome P-450 monooxygenase.
When Schwartzman et al [1211 incubated isolated thick
ascending limb cells from the rabbit outer medulla with 14C-
arachidonic acid, two oxygenated peaks were identified on
HPLC which differed in retention time from lipoxygenase
products, were inhibited by SKF-525A, an inhibitor of lipoxy-
genase and P450 systems, and were increased when the cy-
tochrome P450 system was induced. The same group also found
that one of these products inhibited the (NaK) ATPase and
the other relaxed vascular smooth muscle [122]. Formation of
these products by medullary thick ascending limb cells was
enhanced by vasopressin and calcitonin [122] and in cells
isolated from rabbits previously made hypertensive due to
aortic coarctation [123]. Drugge, Carroll and McGiff [124]
characterized arachidonic acid metabolism in medullary thick
ascending limb cells in culture. Cultured cells did not produce
the two P450 peaks seen in freshly isolated cells. The cells
could, however, be induced with hemin and epidermal growth
factor to produce two different arachidonate products that
migrated by thin layer chromatography in the region of cy-
tochrome P450 products. Only one of these products, however,
was NADPH-dependent when studied in broken cell prepara-
tions.
Effects of P450 products on renal function. Besides the
actions of P450 products to inhibit (NaK) ATPase and relax
blood vessels as described above, other physiological roles for
these products have been proposed. Schlondorff et al [125]
found that each of three epoxyeicosatrienoic acids (5,6-, 11,12-
and 14,l5-EET) inhibited vasopressin-stimulated osmotic water
flow across the toad urinary bladder. The vicinal diol hydrolysis
products of these compounds, the dihydroxyeicosatrienoic ac-
ids, had effects similar to the EET's. Both 5,6-EET and
11,1 2-EET prevented the AVP-induced increase in intracellular
cAMP levels. ll,12-DHET inhibited AVP-induced stimulation
of adenylate cyclase in broken cell preparations.
We have reported [126] that antagonists of the P450 system
markedly inhibit mesangial cell proliferation and mRNA levels
of the immediate early genes, Egr-1 and c-fos. These data
suggest a role for endogenous cytochrome P450 products of
arachidonic acid in the regulation of renal cell growth.
Arachidonic acid as an intracellular messenger
Free arachidonic acid has been shown to regulate the activ-
ities of several enzymes involved in intracellular signalling,
including protein kinase C [127—129], phospholipase C [130] and
Ca2-calmodulin dependent protein kinase [1311. It has also
been reported that arachidonic acid can release Ca2 from
intracellular stores that appear to be distinct from those stores
sensitive to inositol trisphosphate [132]. Arachidonic acid has
been reported to play a pivotal role in the mediation of the
interleukin 2 signal for y interferon production [133—135].
Role of arachidonic acid products in renal tubulointerstitial
disease processes
Arachidonic acid and its metabolites may be involved in
tubulointerstitial inflammatory processes in a number of dif-
ferent ways. Interstitial cell infiltration is an almost invariant
essential component of tubulointerstitial disease. Most of the
mononuclear cells in the interstitium are T cells and many have
the appearance and carry markers of activated lymphocytes. In
acute interstitial nephritis of various etiologies there are abun-
dant numbers of T4+ (T helper cells) and T8÷ (suppressor!
cytotoxic cells) lymphocytes with various ratios of cell popula-
tions reported [136].
In the rejecting transplant there is a heavy infiltrate of cells
bearing the T8 phenotype of cytotoxic T cells [137—1391. As
rejection becomes more severe there is a marked infiltration of
macrophages [140]. It is possible that arachidonic acid itself
may activate protein kinase C in T-cells, thus providing one of
the signals necessary to activate the T cell to generate IL-2,
although this has not been shown. It is known that phorbol
esters (activators of protein kinase C) are more potent stimuli
than interleukin I (IL-l) of T cell IL-2 production. IL-2 results
in clonal proliferation and continued viability of activated T
cells. IL-2 stimulates phospholipid turnover and arachidonic
acid release from IL-2 dependent cell lines [141] and arachi-
donic acid and its lipoxygenase products may play a central role
in y-interferon production [133, 134]. Gamma-interferon upreg-
ulates MHC class II antigens [142—144], which are expressed on
proximal tubular cells in various inflammatory states [145—147].
Prostaglandin E1 has been found to be immunosuppressive in
a murine model of interstitial nephritis. This suppressive effect
was associated with a reduction in spleen cell-product-induced
effector Lyt2+ T cells [148].
Products of arachidonic acid may affect macrophage function
and hence alter the inflammatory response. Tumor necrosis
factor (TN F), also called cachectin, is a polypeptide cytokine
produced primarily by monocytes and macrophages in response
to endotoxin or other immune and inflammatory stimuli [149].
PGE2 reduces TNF production by stimulated macrophages
[144] and HL-60 promyelocytic leukemic cells [150] by an
action which occurs at the level of TNF-gene transcription.
There is also evidence in the HL-60 cells that non-cyclooxyge-
nase metabolites of arachidonic acid may be involved in the
control of TNF gene transcription, since phorbol ester-induced
enhancement of TNF gene expression is inhibited by ketocono-
zole but not indomethacin. Furthermore, leukotriene B4 increases
TNF mRNA levels [150]. TNF stimulates IL-l production by
macrophages, increases neutrophil-mediated antibody-dependent
cytotoxicity [151], phagocytosis [152], and superoxide produc-
tion [153], and also induces class II antigen expression. Arachi-
donic acid plays an important role in the mitogenic and cyto-
toxic effects of TNF in a number of different cell types
[154—156].
Mangino et al [157] reported that the canine cortex, but not
medulla, of kidneys undergoing rejection, synthesizes signifi-
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cantly greater quantities of 12-HETE than normal or autotrans-
planted control renal cortex. Production of LTB4 was signifi-
cantly greater in the rejecting cortex compared with control
renal cortex. The histological appearance of tissue destruction
and cellular infiltration correlated with the amount of 12-HETE
found in the allograft. The dual cyclooxygenase/lipoxygenase
inhibitor (BW 755C) reduced levels of 12-HETE and LTB4 as
well as cellular infiltration and tissue damage in rejecting renal
allografts [1581. Selective cyclooxygenase inhibition with indo-
methacin did not improve allograft function [1581. Thus lipoxy-
genase products may be important for allograft rejection. It is
not clear from these studies, however, whether the lipoxygen-
ase products were derived from the infiltrating cells or from the
renal cells themselves.
With various infectious processes there is enhanced renal
blood flow and natriuresis [159—1611. These changes in renal
blood flow and sodium excretion may be mediated by pros-
taglandins [162]. Many of the physiological changes associated
with infection are believed to be secondary to IL-i [163]. This
cytokine, when injected into the rat, causes a marked natriure-
sis and associated enhanced PGE2 excretion [73]. Indomethacin
completely abolished the IL-i induced natriuresis. It was con-
sequently proposed that IL-i is an important stimulus for PGE2
synthesis in the kidney during infection and POE2 mediates the
natriuresis [73]. This effect of IL-l may be mediated by en-
hanced PGE2 production by the papillary collecting duct [26].
Hydronephrosis results in renal tubulointerstitial inflamma-
tion and is characterized by marked stimulation of renal arachi-
donic acid metabolism. Needleman and colleagues have used
the hydronephrotic kidney as a model to explore the role of
arachidonic acid metabolism in monocytic infiltration into renal
parenchyma and proliferation of fibroblast-like interstitial cells
[159]. The mononuclear cells are critical for the enhanced
prostaglandin and thromboxane release observed with endo-
toxin and bradykinin infusion in this model [159]. Whereas the
inflammatory cell agonist fMLP has no effect upon leukotriene
synthesis in the normal kidney, it enhances leukotriene B4 and
C4 in the hydronephrotic kidney, presumably by acting upon
the monocytes. Albrightson et al [164] have proposed that
leukotriene-induced thromboxane synthesis may represent an
important vasoconstrictive influence in renal inflammation. In a
recent study [1651 this group proposed that an eicosanoid,
possibly a leukotriene, but not thromboxane A2, mediated the
inflammatory cell infiltration.
Conclusions
In this overview we have briefly outlined various aspects of
arachidonic acid metabolism and the multiple ways in which
arachidonic acid and its metabolites influence renal function. In
the coming years we will undoubtedly learn more about the
regulation of the various metabolic pathways and recognize
additional roles played by the various metabolites in renal
function. In particular, we suspect that the noncyclooxygenase
products of arachidonic acid will be recognized as playing
prominent roles in intracellular signalling and control of prolif-
eration, as well as cell-cell interactions in a number of physio-
logical and pathophysiological states.
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